Icagen, Inc.
4222 Emperor Boulevard
Suite 350
Durham
North Carolina
27703
United States
Tel: 919-941-5206
Fax: 919-941-0813
Website: http://www.icagen.com/
Email: info@icagen.com
About Icagen, Inc.
Icagen, Inc. is a public biopharmaceutical company focused on the discovery, development and commercialization of novel, orally-administered, small-molecule drugs that modulate ion channel targets. Using our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates. Our two most advanced programs are:
We are also conducting ongoing drug discovery programs focused on new therapeutics for pain and inflammatory disorders. In each of these programs, we have identified small-molecule compounds that have demonstrated activity on specific ion channels. When we tested these compounds in preclinical studies, they showed desired activities and profiles, validating these ion channels as potential therapeutic targets for the particular indication. In addition to our internal programs, we have established a collaboration with Pfizer Inc focused on three sodium channel targets for the treatment of pain and related disorders. We plan to generate revenue from any product candidates that we successfully develop either through direct sales, collaboration arrangements with leading pharmaceutical and biotechnology companies, or a combination of these approaches.
For further information, see www.icagen.com.
Last Updated: 05-19-2008
177 articles about Icagen, Inc.
-
Icagen, Inc. Reports Top Line Results of Phase IIa Study of Senicapoc in Allergic Asthma
9/1/2009
-
Icagen, Inc. to Present At Upcoming Healthcare Conferences
8/31/2009
-
Icagen, Inc. Reports Second Quarter 2009 Financial Results
8/4/2009
-
Icagen, Inc. Completes Enrollment in Phase II Exercise Induced Asthma Trial
6/12/2009
-
Icagen, Inc. Provides Strategic Update
6/5/2009
-
Icagen, Inc. Reports First Quarter 2009 Financial Results and Operational Highlights
5/5/2009
-
Icagen, Inc. Presents Results of Phase I Program of ICA-105665
4/17/2009
-
Icagen, Inc. to Present Results of Phase I Program of ICA-105665
4/14/2009
-
Xmark Corporation Requests That Icagen, Inc. Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign
4/1/2009
-
Icagen, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
3/11/2009
-
Icagen, Inc. Initiates Study of Senicapoc in Exercise Induced Asthma
3/11/2009
-
Icagen, Inc. to Announce Fourth Quarter and Full Year 2008 Results and Conduct Conference Call On March 11, 2009
2/27/2009
-
Icagen, Inc. to Present At the 11th Annual BIO CEO & Investor Conference On February 10, 2009
2/2/2009
-
Icagen, Inc. to Present At the JP Morgan Healthcare Conference On January 15, 2009
1/6/2009
-
Icagen, Inc. Adopts Shareholder Rights Plan
12/3/2008
-
Icagen, Inc. Reports Third Quarter 2008 Financial Results
11/6/2008
-
Icagen, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference on November 10, 2008
11/3/2008
-
Icagen, Inc. to Report Third Quarter 2008 Results On November 6, 2008
10/30/2008
-
Icagen, Inc. to Present at Seventh Annual Biotechnology Industry Organization (BIO) Investor Forum on October 29, 2008
10/22/2008
-
Icagen, Inc. Initiates Phase II Proof-of-Concept Trial in Allergic Asthma for Senicapoc Potassium Channel Blocker
10/9/2008